|
業務類別
|
Biotechnology |
|
業務概覽
|
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain. |
| 公司地址
| 200-3650 Gilmore Way, Burnaby, BC, CAN, V5G 4W8 |
| 電話號碼
| +1 604 484-3300 |
| 傳真號碼
| +1 604 484-3450 |
| 公司網頁
| https://www.xenon-pharma.com |
| 員工數量
| 327 |
| Mr. Thomas P. Kelly |
Chief Financial Officer and Principal Accounting Officer |
-- |
26/02/2026 |
| Mr. Ian C. Mortimer |
Director, Chief Executive Officer, President and Principal Operating Officer |
美元 714.59K |
26/02/2026 |
| Mr. Christopher John Kenney |
Chief Medical Officer |
美元 540.00K |
24/04/2025 |
| Ms. Andrea DiFabio |
Chief Legal Officer and Corporate Secretary |
美元 490.00K |
24/04/2025 |
|
|
| Mr. Justin David Gover |
Independent Director |
26/02/2026 |
| Dr. Gillian M. Cannon, PhD |
Independent Director |
26/02/2026 |
| Mr. Patrick C. Machado, J.D. |
Independent Director |
26/02/2026 |
| Mr. Gary Patou, M.D. |
Independent Director |
26/02/2026 |
| Mr. Ian C. Mortimer |
Director, Chief Executive Officer, President and Principal Operating Officer |
26/02/2026 |
| Ms. Dawn A. Svoronos |
Chairman of the Board |
26/02/2026 |
| Mr. Steven Gannon |
Independent Director |
26/02/2026 |
| Dr. Elizabeth A. Garofalo, M.D. |
Independent Director |
26/02/2026 |
|
|
|
|
